Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma

Monique Hartley-Brown, Craig E. Cole, Pamela Price, Michael Andreini, George Mulligan, Anne Quinn Young, Hearn Jay Cho

Research output: Contribution to journalShort surveypeer-review


Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other burdens of trial participants, selecting diverse study sites, including implicit bias training, and taking steps to empower patients.

Original languageEnglish
Pages (from-to)32-39
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number1
StatePublished - Jan 2024


  • Clinical trial
  • Diversity
  • Equity
  • Inclusivity
  • Multiple myeloma


Dive into the research topics of 'Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma'. Together they form a unique fingerprint.

Cite this